Nutritional Primary Prevention of Type 1 Diabetes

1 型糖尿病的营养一级预防

基本信息

项目摘要

The overall objective of the project is to determine whether weaning to a casein hydrolysate (Nutramigen TM) during at least the first 6 months of life reduces the incidence of Type 1 diabetes in genetically susceptible children. Specific Aims I-a: To determine, if weaning to casein hydrolysate reduces the frequency of diabetes-predictive autoantibodies in subjects with risk-associated HLA genotype and a first degree relative with type 1 diabetes. I-b: To determine, if weaning to casein hydrolysate reduces the frequency of clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree relative. Newborn infants, who have increased genetic risk and first degree relatives with type 1 diabetes (mother, father or sibling has the disease, and HLA genotyping shows the subject to belong to the increased risk group) will be invited for the study. An international, multicenter, double blind, randomized, controlled trial of 2 different nutritional supplements will be performed. The newborn infants will be randomly allocated to receive after breast feeding 1 of 2 formulas during at least the first 6 months of life (the intervention period). The test formula will be a casein hydrolysate, free of intact cows milk proteins. The casein hydrolysate is not diabetogenic in the NOD mouse. The control formula will be similar to a commonly used cow milk based infant formula. Subjects will be followed during and after the intervention period for 6 and 10 years time during which serological markers are measured and the development of diabetes will be recorded. Such a clinical trial is necessary to get a definite answer to the hypothesis. Recruitment is carried out during a 2-year period in the U.S., Canada and 15 other countries. The estimated number of subjects participating in the randomized nutritional prevention study is approximately 2,800. This requires that genetic screening would be performed in approximately 6,200 newborn infants. The study question has important public health implications.
该项目的总体目标是确定至少在出生后的前6个月内断奶使用酪蛋白水解物(Nutramigen TM)是否会降低遗传易感儿童的1型糖尿病发病率。具体目标一a:确定在具有风险相关HLA基因型和1型糖尿病一级亲属的受试者中,停用酪蛋白水解物是否能降低糖尿病预测性自身抗体的频率。I-b:为了确定,如果断乳酪蛋白水解物降低风险相关的HLA基因型和受影响的一级亲属的受试者的临床糖尿病的频率。将邀请遗传风险增加的新生儿和1型糖尿病一级亲属(母亲、父亲或兄弟姐妹患有该疾病,HLA基因分型显示受试者属于风险增加组)参加研究。将对2种不同的营养补充剂进行国际、多中心、双盲、随机、对照试验。新生儿将被随机分配,在出生后至少6个月(干预期)内接受2种配方奶粉中的1种。试验配方为酪蛋白水解产物,不含完整的牛奶蛋白。酪蛋白水解产物在NOD小鼠中不具有致糖尿病性。对照配方食品将类似于常用的基于牛乳的婴儿配方食品。将在干预期间和之后对受试者进行6年和10年的随访,在此期间测量血清学标志物并记录糖尿病的发展。要想对这一假设得到明确的答案,这样的临床试验是必要的。招聘在美国进行,为期2年,加拿大和其他15个国家。估计参与随机营养预防研究的受试者人数约为2,800人。这需要对大约6 200名新生儿进行基因筛查。研究问题具有重要的公共卫生意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DOROTHY J BECKER其他文献

DOROTHY J BECKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DOROTHY J BECKER', 18)}}的其他基金

JUVENILE DIABETES MELLITUS: EPIDEMIOLOGY AND ETIOLOGY
青少年糖尿病:流行病学和病因学
  • 批准号:
    8034945
  • 财政年份:
    2010
  • 资助金额:
    $ 73.29万
  • 项目类别:
EFFECTS OF HYPOGLYCEMIA ON COGNITIVE FUNCTION IN CHILDREN WITH IDDM
低血糖对 IDDM 儿童认知功能的影响
  • 批准号:
    7203097
  • 财政年份:
    2005
  • 资助金额:
    $ 73.29万
  • 项目类别:
ETIOLOGY AND EPIDEMIOLOGY OF INSULIN DEPENDENT DIABETES MELLITUS
胰岛素依赖型糖尿病的病因学和流行病学
  • 批准号:
    7203086
  • 财政年份:
    2005
  • 资助金额:
    $ 73.29万
  • 项目类别:
THE MANAGEMENT OF ASYMPTOMATIC CELIAC DISEASE IN CHILDREN WITH TYPE I DM
I 型糖尿病儿童无症状乳糜泻的治疗
  • 批准号:
    7203120
  • 财政年份:
    2005
  • 资助金额:
    $ 73.29万
  • 项目类别:
Etiology and Epidemiology of Insulin Dependent Diabetes Mellitus
胰岛素依赖性糖尿病的病因学和流行病学
  • 批准号:
    7041275
  • 财政年份:
    2003
  • 资助金额:
    $ 73.29万
  • 项目类别:
The Management of Asymptomatic Celiac Disease in Children with Type I DM
I 型糖尿病儿童无症状乳糜泻的治疗
  • 批准号:
    7041321
  • 财政年份:
    2003
  • 资助金额:
    $ 73.29万
  • 项目类别:
Effects of Hypoglycemia on Cognitive Function in Children with IDDM
低血糖对IDDM儿童认知功能的影响
  • 批准号:
    7041287
  • 财政年份:
    2003
  • 资助金额:
    $ 73.29万
  • 项目类别:
Trial to Reduce IDDM in the Genetically at Risk: A Nutritional primary prevention
减少遗传风险人群 IDDM 的试验:营养一级预防
  • 批准号:
    8041964
  • 财政年份:
    2001
  • 资助金额:
    $ 73.29万
  • 项目类别:
Prediction and Prevention of Type 1 Diabetes - TrialNet
1 型糖尿病的预测和预防 - TrialNet
  • 批准号:
    8076298
  • 财政年份:
    2001
  • 资助金额:
    $ 73.29万
  • 项目类别:
Prediction and Prevention of Type 1 Diabetes - TrialNet
1 型糖尿病的预测和预防 - TrialNet
  • 批准号:
    8025940
  • 财政年份:
    2001
  • 资助金额:
    $ 73.29万
  • 项目类别:

相似海外基金

From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
  • 批准号:
    MR/Y013050/1
  • 财政年份:
    2024
  • 资助金额:
    $ 73.29万
  • 项目类别:
    Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
  • 批准号:
    495575
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
    Operating Grants
Core B: Clinical Trials Core
核心 B:临床试验核心
  • 批准号:
    10554476
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
  • 批准号:
    2884930
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
    Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
  • 批准号:
    10855627
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
  • 批准号:
    10895949
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
  • 批准号:
    10891325
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
  • 批准号:
    10761602
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
  • 批准号:
    10758129
  • 财政年份:
    2023
  • 资助金额:
    $ 73.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了